Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Celltrion : COVID-19 antibody treatment to enter Phase III trial

10/14/2020 | 09:31am EST
COVID-19 antibodies

Celltrion Group has announced the launch of its Phase III clinical trial investigating CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate that could act as a preventative measure. The initiation of the post-exposure prophylaxis clinical trial follows the approval of the Investigational New Drug (IND) application by the Korean Ministry of Food and Drug Safety (MFDS) on 8 October 2020.

The company anticipates the enrolment of approximately 1,000 patients to evaluate population-based prophylaxis in contacts of SARS-CoV-2 infected patients. The post-exposure prophylaxis clinical trial will evaluate the preventive effect and safety of CT-P59 and whether CT-P59 can elicit a neutralising antibody response to prevent the virus from infecting human cells.

"We hope anti-COVID-19 monoclonal antibodies such as CT-P59 can provide high-risk individuals with effective protection against COVID-19 and help prevent further spread in the community," said Dr Sang Joon Lee, Senior Executive Vice President of Celltrion. "We look forward to continued data generation as this trial proceeds and we remain committed to combatting the spread of the virus around the world.”

Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers…

According to the company, CT-P59 has previously shown promising safety results in its Phase I clinical trial in healthy volunteers. The MFDS has now approved Celltrion's IND application to initiate a Phase II/III pivotal trial of this potential treatment in mild-to-moderate patients.

The post Celltrion COVID-19 antibody treatment to enter Phase III trial appeared first on European Pharmaceutical Review.

© Russell Publishing Limited, 2020. All Rights Reserved., source Trade Journals

All news about CELLTRION, INC.
07:31aCELLTRION : Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment
AQ
11/06CELLTRION, INC. : quaterly earnings release
11/05Celltrion's COVID-19 antibody drug cut recovery time-early study
RE
11/05CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
RE
11/04S.Korea shares extend gains as investors eye tight U.S. election race
RE
11/03S.Korea stocks gain most in nearly 5 months on strong global data
RE
10/27S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
RE
10/26S.Korea shares dip as surging global coronavirus cases dent sentiment
RE
10/26South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
RE
10/25S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
RE
More news
Financials
Sales 2020 1 871 B 1,69 B 1,69 B
Net income 2020 583 B 0,53 B 0,53 B
Net cash 2020 498 B 0,45 B 0,45 B
P/E ratio 2020 75,9x
Yield 2020 0,00%
Capitalization 44 130 B 39 870 M 39 849 M
EV / Sales 2020 23 580x
EV / Sales 2021 20 478x
Nbr of Employees 908
Free-Float 68,3%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 313 555,56 KRW
Last Close Price 330 000,00 KRW
Spread / Highest target 36,4%
Spread / Average Target -4,98%
Spread / Lowest Target -63,0%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.82.32%39 870
LONZA GROUP AG55.66%44 931
MODERNA, INC.458.18%43 204
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832
IMMUNOMEDICS, INC.315.22%20 324